MedTrace Logo

Low-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese Children

NCT06763315 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-01-08

No results posted yet for this study

Summary

The goal of this study is to compare the efficacy and safety of low-dose and internationally recommended standard dose of selumetinib in the treatment of plexiform neurofibromas in Chinese children.

Conditions

  • Plexiform Neurofibromas (PN)

Interventions

DRUG

Selumetinib

Use of the internationally recommended standard dose and low dose of the same drug

Sponsors & Collaborators

  • West China Hospital

    lead OTHER

Principal Investigators

  • Yi Ji, MD, PhD · West China Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2028-01-31
Completion
2028-10-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06763315 on ClinicalTrials.gov